World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
46
Citations
15232
World Ranking
4567
National Ranking
2058

Rimas J. Orentas publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Rimas J. Orentas sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 191 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Rimas J. Orentas D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Rimas J. Orentas sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 46 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Rimas J. Orentas is affiliated with the University of Washington in the United States and has a research portfolio focused primarily on the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work encompasses a range of subfields including Oncology, Molecular Biology, Immunology, Genetics, and Physiology.

The main research topics Orentas has contributed to include:

  • CAR-T cell therapy research
  • Viral Infectious Diseases and Gene Expression in Insects
  • Virus-based gene therapy research
  • Immune Cell Function and Interaction
  • Biomedical Ethics and Regulation
  • Biosimilars and Bioanalytical Methods
  • Nanowire Synthesis and Applications

A selection of recent papers featuring Orentas includes:

  • Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial (2020, Nature Medicine)
  • Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis (2021, Nature Medicine)
  • Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety (2022, Cancer Discovery)
  • Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice (2020, Gastroenterology)
  • Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models (2021, Science Translational Medicine)

Orentas frequently collaborates with several researchers, including:

  • Boro Dropulić
  • Michael C. Jensen
  • Dina Schneider
  • Ashley Wilson
  • Rebecca Gardner

Their work is regularly published in a set of scientific venues such as:

  • Cancer Research
  • Blood
  • Regular and Young Investigator Award Abstracts
  • Frontiers in Immunology
  • Neuro-Oncology

Best Publications

  • T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

    Daniel W Lee;James N Kochenderfer;Maryalice Stetler-Stevenson;Yongzhi K Cui

  • 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

    Adrienne H Long;Waleed M Haso;Jack F Shern;Kelsey M Wanhainen

  • CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

    Terry J Fry;Nirali N Shah;Rimas J Orentas;Maryalice Stetler-Stevenson

  • Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

    Waleed Haso;Daniel W. Lee;Nirali N. Shah;Maryalice Stetler-Stevenson

  • CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

    Robbie G. Majzner;Johanna L. Theruvath;Anandani Nellan;Sabine Heitzeneder

  • Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

    Nirav N. Shah;Bryon D. Johnson;Dina Schneider;Fenlu Zhu

  • Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase

    Alec J. Walker;Robbie G. Majzner;Ling Zhang;Kelsey Wanhainen

  • Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation.

    James E. K. Hildreth;Rimas J. Orentas

  • CD19 CAR T cell product and disease attributes predict leukemia remission durability

    Olivia C. Finney;Hannah Brakke;Stephanie Rawlings-Rhea;Roxana Hicks

  • Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.

    Adrienne H. Long;Steven L. Highfill;Yongzhi Cui;Jillian P. Smith

  • Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

    Nicholas A. Vitanza;Nicholas A. Vitanza;Adam J. Johnson;Adam J. Johnson;Ashley L. Wilson;Ashley L. Wilson;Christopher Brown;Christopher Brown

  • A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

    Dina Schneider;Ying Xiong;Darong Wu;Volker Nӧlle

  • Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV

    Rimas J. Orentas;James E. K. Hildreth

  • Towards a commercial process for the manufacture of genetically modified T cells for therapy

    A D Kaiser;M Assenmacher;B Schröder;M Meyer

  • Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine

    Rimas J. Orentas;James E K Hildreth;Eugene Obah;Michael J Polydefkis

  • Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer

    Hua Zhang;Irena Maric;Michael J. DiPrima;Javed Khan

  • Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.

    Kim Anthony-Gonda;Ariola Bardhi;Alex Ray;Nina Flerin

  • The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer

    Daniel W. Lee;David M. Barrett;Crystal Mackall;Rimas Orentas

  • Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice

    Dan Li;Dan Li;Nan Li;Yi-Fan Zhang;Haiying Fu;Haiying Fu

  • Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers

    Rimas J. Orentas;James J. Yang;Xinyu Wen;Jun S. Wei

  • Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

    Haiying Qin;Monica Cho;Waleed Haso;Ling Zhang

Frequent Co-Authors

Crystal L. Mackall
Crystal L. Mackall Stanford University
Bryon D. Johnson
Bryon D. Johnson Medical College of Wisconsin
Terry J. Fry
Terry J. Fry University of Colorado Denver
Dimiter S. Dimitrov
Dimiter S. Dimitrov University of Pittsburgh
Javed Khan
Javed Khan National Institutes of Health
Michael C. Jensen
Michael C. Jensen Seattle Children's Hospital
Ira Pastan
Ira Pastan Center for Cancer Research
Poul H. Sorensen
Poul H. Sorensen University of British Columbia
David M. Barrett
David M. Barrett Children's Hospital of Philadelphia
Els Verhoeyen
Els Verhoeyen Inserm : Institut national de la santé et de la recherche médicale

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA can open doors to various allied healthcare roles. For those interested in patient care and research, pursuing nursing degrees online is a popular pathway. Many students explore accelerated nurse practitioner programs to fast-track their careers with advanced clinical training.

If you’re starting without a nursing background, enrolling in online RN programs for non nurses can provide a flexible route into registered nursing. These programs cater to career changers and equip graduates with essential skills in immunology-related patient care.

For those aiming to begin their nursing education quickly, considering easiest ABSN programs to get into offers a streamlined approach to obtaining a Bachelor of Science in Nursing. These programs often balance quality education with more accessible admission criteria.

Another entry point into healthcare is through fastest and easiest LPN programs, which prepare students for practical nursing roles within a shorter timeframe. This can be a valuable step for individuals looking to work alongside immunology specialists in clinical settings.

Best Scientists Citing Rimas J. Orentas

Trending Scientists

Recently Published Articles